We are live on
!
Find out more
LP
Longview Partners Portfolio holdings
AUM
$7.06B
1-Year Est. Return
3.43%
This Fund
S&P 500
This Quarter
Est. Return
+0.36%
1 Year Est. Return
-3.43%
3 Year Est. Return
+28.48%
5 Year Est. Return
+46.59%
10 Year Est. Return
+218.87%
AUM
$19.1B
AUM Growth
-$23.3M
(-0.12%)
Cap. Flow
-$35.7M
Cap. Flow
% of AUM
-0.19%
Top 10 Holdings %
Top 10 Hldgs %
50.97%
Holding
26
New
4
Increased
5
Reduced
16
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Henry Schein
HSIC
|
+$981M |
| 2 |
Medtronic
MDT
|
+$580M |
| 3 |
TJX Companies
TJX
|
+$244M |
| 4 |
AGN
Allergan plc
AGN
|
+$166M |
| 5 |
IQVIA
IQV
|
+$31.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aptiv
APTV
|
+$378M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$308M |
| 3 |
W.W. Grainger
GWW
|
+$280M |
| 4 |
Parker-Hannifin
PH
|
+$261M |
| 5 |
FISV
Fiserv Inc
FISV
|
+$229M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.28% |
| 2 | Financials | 23.72% |
| 3 | Industrials | 17.1% |
| 4 | Technology | 13.95% |
| 5 | Consumer Staples | 5.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
W.W. Grainger
GWW
$66B
| $1.15B | 6.05% |
4,089,899
-1,067,891
| -21% | -$280M |
|
2
Dollar General
DG
$27.8B
| $984M | 5.16% |
10,514,664
-903,194
| -8% | -$86.8M |
|
3
Fidelity National Information Services
FIS
$23.2B
| $984M | 5.16% |
10,213,002
-73,360
| -0.7% | -$7.2M |
|
4
Aon
AON
$81.4B
| $971M | 5.09% |
6,921,597
-313,060
| -4% | -$43.8M |
|
|
5
IQVIA
IQV
$40B
| $960M | 5.03% |
9,789,620
+315,176
| +3% | +$31.9M |
|
6
Willis Towers Watson
WTW
$29.9B
| $942M | 4.94% |
6,190,732
+44,513
| +0.7% | +$6.99M |
|
7
Emerson Electric
EMR
$85B
| $939M | 4.92% |
13,744,085
-578,750
| -4% | -$41.2M |
|
8
HCA Healthcare
HCA
$92.8B
| $938M | 4.91% |
9,665,962
-2,356,554
| -20% | -$229M |
|
|
9
Henry Schein
HSIC
$9.76B
| $933M | 4.89% |
+17,707,167
| New | +$981M |
|
|
BNY
10
Bank of New York Mellon
BNY
$106B
| $918M | 4.81% |
17,820,784
+145,500
| +0.8% | +$8.09M |
|
11
Pfizer
PFE
$144B
| $915M | 4.8% |
27,187,933
-62,554
| -0.2% | -$2.15M |
|
12
Oracle
ORCL
$346B
| $909M | 4.76% |
19,865,311
+63,800
| +0.3% | +$3.17M |
|
13
Wells Fargo
WFC
$263B
| $889M | 4.66% |
16,968,727
-281,400
| -2% | -$16.7M |
|
14
UnitedHealth
UNH
$389B
| $884M | 4.63% |
4,128,910
-615,545
| -13% | -$141M |
|
15
Zimmer Biomet
ZBH
$18.5B
| $855M | 4.48% |
8,077,378
-191,264
| -2% | -$22.2M |
|
16
State Street
STT
$50.2B
| $803M | 4.21% |
8,052,671
-78,852
| -1% | -$8.26M |
|
|
17
Thermo Fisher Scientific
TMO
$214B
| $704M | 3.69% |
3,410,530
-1,466,360
| -30% | -$308M |
|
|
18
Parker-Hannifin
PH
$125B
| $694M | 3.64% |
4,058,397
-1,379,043
| -25% | -$261M |
|
|
19
Medtronic
MDT
$111B
| $564M | 2.96% |
+7,029,480
| New | +$580M |
|
|
FISV
20
Fiserv Inc
FISV
$28.9B
| $545M | 2.86% |
7,637,592
-3,259,746
| -30% | -$229M |
|
|
TMX
21
DELISTED
Terminix Global Holdings, Inc.
TMX
| $476M | 2.49% |
13,968,050
-317,125
| -2% | -$11M |
|
22
Omnicom Group
OMC
$24.6B
| $472M | 2.48% |
6,497,089
+141,210
| +2% | +$10.6M |
|
|
23
TJX Companies
TJX
$178B
| $251M | 1.32% |
+6,163,834
| New | +$244M |
|
24
Arrow Electronics
ARW
$10.8B
| $225M | 1.18% |
2,922,491
-30,830
| -1% | -$2.5M |
|
|
AGN
25
DELISTED
Allergan plc
AGN
| $167M | 0.87% |
+990,123
| New | +$166M |
|
Similar funds
IGAM
NAMA
RPI
MNA
CWM
SC
OCA
DE
Longview Partners's Q1 2018 Portfolio in Review
As of Q1 2018, Longview Partners held 26 positions worth $19.1B, down 0.12% from $19.1B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Longview Partners's Q1 2018 filing shows 4 new, 5 increased, 16 reduced and 1 closed positions. Its largest new stake was Henry Schein: 17,707,167 shares worth $933M. The largest sale was Aptiv, an estimated $378M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 31% a quarter earlier, followed by Financials and Industrials.
- Longview Partners's largest Q1 2018 buy was Henry Schein: 17,707,167 shares worth $933M.
- Longview Partners added most to IQVIA in Q1 2018, an estimated $31.9M increase.
- Longview Partners's biggest Q1 2018 reduction was Thermo Fisher Scientific, cutting an estimated $308M.
- Longview Partners fully exited Aptiv in Q1 2018, selling an estimated $378M.
- Longview Partners's ten largest holdings make up 51% of its $19.1B portfolio in Q1 2018.
- Longview Partners opened 4 new positions and closed 1 in Q1 2018.
- Longview Partners's portfolio value fell 0.12% quarter-over-quarter to $19.1B.
Based on Longview Partners's 13F filing for Q1 2018, filed 16 Apr 2018.